04K.F Knight Therapeutics Inc
- Market cap
- EUR 742M
- P/E
- 75.5x
- P/B
- 1.43x
- ROE
- 1.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 04K.F undervalued?
Graham number04K.F trades 119.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Knight Therapeutics Inc fundamental analysis
No fundamental analysis for Knight Therapeutics Inc yet.
Knight Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Knight Therapeutics Inc
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemoth…
Full company profileKnight Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Knight Therapeutics Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.94M | 8.63M | 12.5M | 47.5M | 200M | 243M | 294M | 328M | 371M | 450M | 574M |
| Gross Profit | 4.39M | 7.05M | 10.2M | 26.9M | 81.7M | 115M | 138M | 153M | 174M | 200M | 276M |
| Operating Income | -7.84M | -8.91M | -5.78M | -12.7M | -30.0M | -12.8M | -17.1M | 6.37M | 7.40M | -2.35M | 33.4M |
| EBITDA | - | -7.28M | -3.85M | 28.1M | 67.6M | 58.2M | 25.3M | 40.9M | 64.4M | 60.3M | 81.8M |
| Net Income | 18.6M | 17.2M | 24.1M | 14.5M | 42.1M | 15.7M | -29.9M | -16.8M | 4.33M | -5.37M | 9.50M |
| EPS | - | 0.12 | 0.17 | 0.11 | 0.32 | 0.13 | -0.27 | -0.17 | 0.04 | -0.05 | 0.10 |
| Balance Sheet | |||||||||||
| Total Assets | 991M | 1.01B | 1.05B | 1.31B | 1.04B | 992M | 1.05B | 945M | 964M | 1.05B | 1.07B |
| Total Liabilities | 11.1M | 14.8M | 21.8M | 390M | 153M | 150M | 229M | 199M | 169M | 279M | 270M |
| Shareholders' Equity | 980M | 991M | 1.03B | 811M | 886M | 842M | 826M | 747M | 795M | 767M | 795M |
| Cash & Short-term Investments | 515M | 496M | 245M | 169M | 230M | 86.0M | 71.7M | 58.8M | 80.1M | 76.4M | 121M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 14.7M | 23.5M | -5.74M | 4.60M | -12.2M | 44.6M | 40.5M | 35.9M | 36.3M | 69.0M | 128M |
| Capital Expenditure | 9.86M | 126K | 202K | 109K | 5.38M | 3.83M | 25.8M | 9.96M | 31.5M | 33.7M | 18.9M |
| Free Cash Flow | - | 23.3M | -9.61M | 1.65M | -32.9M | -180M | 14.7M | 26.0M | 4.81M | 35.3M | 109M |
| Ratios | |||||||||||
| ROE | 1.9% | 1.7% | 2.3% | 1.8% | 4.7% | 1.9% | -3.6% | -2.3% | 0.5% | -0.7% | 1.2% |
| ROA | 1.9% | 1.7% | 2.3% | 1.1% | 4.0% | 1.6% | -2.8% | -1.8% | 0.4% | -0.5% | 0.9% |
| Net Profit Margin | 312.5% | 199.7% | 192.6% | 30.6% | 21.1% | 6.4% | -10.2% | -5.1% | 1.2% | -1.2% | 1.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Knight Therapeutics Inc dividends
Knight Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns Knight Therapeutics Inc
- Insiders 46.00%
- Institutions 18.98%
- Public & others 35.02%
- Shares outstanding 98.3M
- Free float 60.6M
Knight Therapeutics Inc company profile
- Company name
- Knight Therapeutics Inc
- Ticker
- 04K.F
- ISIN
- CA4990531069
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 830
- Fiscal year end
- December
- Address
- 100 Boul. Alexis-Nihon, Montreal, QC, Canada, H4M 2P2
- Phone
- 514-484-4483
- Website
- knighttx.com
About Knight Therapeutics Inc
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.
Knight Therapeutics Inc management
10- Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A.Executive Chairman · born 1969
- Ms. Samira Sakhia BCom, CA, CPA, MBAPresident, CEO & Director · born 1968
- Mr. Arvind UtchanahChief Financial Officer
- Mr. Leopoldo BosanoVice-President of Manufacturing & Operations
- Ms. Susan Caroline EmblemGlobal Vice President of Human Resources
- Ms. Amal Khouri B.Sc., M.B.A.Chief Business Officer
- Ms. Christine PoulinGeneral Manager of Canada
- Ms. Monica PercarioGlobal Vice President of Regulatory & Quality
- Mr. Henrique DiasGlobal Vice President of Marketing
- Ms. Melanie GroleauGlobal Vice President of Medical & Clinical